IONS IONIS PHARMACEUTICALS INC — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$53.39

Period return

-28.40 (-34.72%)

Volume

3.0M

2026-07-21O $52.75 H $54.13 L $52.26 C $53.39MA5 $54.02MA20 $69.56MA60 $73.04MA120 $75.33

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 05.Highin 15 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 19.MediumBUY2 months ago
Citigroup: Buy
US analyst rating / recommendation change.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.38%
2026. 05. 01.LowBUY3 months ago
RBC Capital: Outperform
US analyst rating / recommendation change.
2026. 05. 01.LowBUY3 months ago
Barclays: Overweight
US analyst rating / recommendation change.
2026. 04. 30.LowBUY3 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 04. 24.LowBUY3 months ago
TD Cowen: Buy
US analyst rating / recommendation change.
2026. 04. 22.MediumBUY3 months ago
Canaccord Genuity: Buy
US analyst rating / recommendation change.
2026. 04. 22.LowBUY3 months ago
Morgan Stanley: Overweight
US analyst rating / recommendation change.
2026. 04. 10.LowBUY3 months ago
B of A Securities: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $100.92 · 25 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 05.	After market close (AMC)	$-0.87	—	—	$189.64M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-0.93	—	—	$131.61M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-2.38	—	—	$478.56M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-1.43	—	—	$344.75M	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	5,857,629	$439.85M	0.38%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	2,658,646	$210.33M	0.33%	—	New position

IONIS PHARMACEUTICALS INC

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 19.	Citigroup	—	Initiate coverage	— → Buy	—	Citigroup: Buy
2026. 05. 01.	RBC Capital	—	Maintain	Outperform → Outperform	—	RBC Capital: Outperform
2026. 05. 01.	Barclays	—	Maintain	Overweight → Overweight	—	Barclays: Overweight
2026. 04. 30.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 04. 24.	TD Cowen	—	Maintain	Buy → Buy	—	TD Cowen: Buy
2026. 04. 22.	Canaccord Genuity	—	Initiate coverage	— → Buy	—	Canaccord Genuity: Buy